Anticoagulant News and Research

RSS

Thickening of arterial walls causes branch retinal vein occlusion

Branch retinal vein occlusion - blockage of the blood vessels that channel blood from the retina - is a common eye disease. A type of blood clot in the eye, the disease causes reduced vision, and people with the disease also typically have an increased risk of hypertension, diabetes and other serious conditions. A young scientist from the University of Copenhagen has made a significant contribution to finding the cause of the disease.

21 Dec 2012

Concern over enoxaparin bleeding risk in patients with moderate renal impairment

The low molecular weight heparin enoxaparin is associated with an increased risk for major bleeding in patients who have moderate renal impairment, say US scientists in findings that have prompted calls for updates to dosing recommendations.

14 Dec 2012

Researchers decipher mechanism by which anophelin binds to thrombin

An international project lead by the Molecular and Cell Biology Institute of Porto University with the participation of researchers from IMIM (Hospital del Mar Medical Research Institute) has, for the first time ever, deciphered the mechanism by which a substance called anophelin binds to an enzyme (thrombin) involved in the process of blood coagulation.

12 Dec 2012

Some stroke patients may benefit from cerebral angioplasty and stent placement

Some stroke patients may benefit from cerebral angioplasty and stent placement, according to a new study published online in the journal Radiology.

11 Dec 2012

Hemorrhage risk ‘higher than reported’ for AF warfarin users

Real-world findings for atrial fibrillation patients using warfarin point to a significantly higher risk for hemorrhage than reported for clinical trials.

28 Nov 2012

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

21 Nov 2012

Antibody-coated stents carry increased risk of myocardial infarction and re-operation

If narrowed or blocked coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. Drug-coated stents are preferred for patients at high risk of renewed narrowing of vessels (restenosis). However, the use of antibody-coated stents has been increasing in recent years. Current studies provide indications that these new antibody-coated stents more frequently lead to myocardial infarction and make re-operation necessary.

15 Nov 2012

WU researchers to study blood-clotting disorders

Researchers at Washington University School of Medicine in St. Louis have received a $9 million grant to investigate blood-clotting disorders. From heart attacks and strokes to uncontrolled bleeding, clotting disorders cause more deaths each year in the United States than all types of cancer combined.

7 Nov 2012

Low-dose aspirin effective at preventing serious blood clots

Low-dose aspirin is a cheap and effective way to prevent potentially deadly blood clots in the leg or the lungs in patients who have had a previous blood clot a new study shows.

6 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.

3 Nov 2012

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).

29 Oct 2012

UK remains at risk of devastating stroke crisis, new report confirms

The UK remains at risk of a devastating stroke crisis, according to UK health experts launching Reports published today, on World Stroke Day, by Action for Stroke Prevention, an alliance of renowned health experts and patient organisations.

29 Oct 2012

Europe remains at risk of a devastating stroke crisis

Europe remains at risk of a devastating stroke crisis, according to a major new Report, "How Can We Avoid a Stroke Crisis in Europe?" published today, on World Stroke Day, by Action for Stroke Prevention (ASP).

29 Oct 2012

New anti-thrombotic treatments in AF patients can reduce risk of stroke

Atrial fibrillation, whose prevalence continues to rise, was described last year as the "new epidemic" in cardiovascular disease, even though AF can be successfully controlled by the detection and management of risk factors, by rhythm control treatments, and by the use of antithrombotic therapies.

29 Oct 2012

SSRI use linked to brain hemorrhage

Use of selective serotonin reuptake inhibitors is associated with an increased risk for brain hemorrhage, particularly intracerebral bleeding, suggest meta-analysis findings.

18 Oct 2012

FDA clears Fenwal's new plasma products

Fenwal Inc., a global leader specializing in separation technologies for blood and cell collection and therapy, announced today it has received clearance from the U.S. Food and Drug Administration for two new indications for collection of plasma products on the Fenwal Alyx and Amicus systems.

8 Oct 2012

Article explores safety and efficacy of aerosol delivery of drugs in ICU patients

Essential medications can be delivered as inhaled drugs to critically ill patients in the Intensive Care Unit (ICU) who require mechanical ventilation to breathe. Aerosol drug delivery is highly complex, however, and if not done properly the medication will not reach the lungs and therapy will be ineffective.

5 Oct 2012

Myocardial infarction mortality rates decrease by 44% over the last 15 years in Argentina

Mortality caused by myocardial infarction has decreased by 44% over the last 15 years in Argentina, according to new research which will be presented during the 38th Argentine Congress of Cardiology.

5 Oct 2012